Researchers from the University of Pittsburgh School of Medicine have linked pulmonary arterial hypertension (PAH), a progressive disease characterized by blood vessel remodeling, with lysosomal dysfunction and sterol metabolism. They reported their results on Jan. 23, 2025, in Science.Read More
Adenoid cystic carcinoma (ACC) is a rare malignancy of the secretory glands with a high tendency to invade adjacent tissue and spread to the lung, bone or liver. No treatments other than surgery or radiotherapy are available, so new therapeutic strategies are urgently needed. Read More
Ymmunobio AG, in collaboration with the Paul Scherrer Institute, has received an Innosuisse grant to develop innovative radioactive loaded antibodies for the treatment and diagnosis of solid tumors based on Ymmunobio’s proprietary YB-800. Read More
Pulmonary fibrosis (PF) is a chronic lung disease characterized by the replacement of normal lung tissue by scar tissue, resulting in worsening lung function and impaired gas exchange. Autotaxin (ATX), the enzyme that produces the lipid mediator lysophosphatidic acid (LPA), is upregulated in lung fibrotic tissue. Read More
Kexing Biopharm Co. Ltd. has outlined progress in its cachexia and autoimmune pipelines, built upon its Kx-Body antibody technology platform and Kx-Fusion fusion protein technology platform. Read More
Researchers from Beijing Institute of Technology (BIT) and affiliated organizations presented the discovery and preclinical characterization of novel soluble epoxide hydrolase 2 (sEH) inhibitors as candidates for the treatment of inflammatory disorders. Read More
Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 monoclonal antibody in traumatic spinal cord injury (SCI). Read More
Hangzhou Bio-Creativity Pharma-Tech Co. Ltd. has disclosed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of atopic dermatitis. Read More
Researchers from Guangzhou Medical University and affiliated organizations presented data from a study that aimed to investigate the disease-causing mechanism of EP400, a gene that encodes the E1A binding protein p400, which is a core catalytic ATPase subunit of ATP-dependent chromatin remodeling complexes. Read More
Genescience Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer. Read More
Silexon Intelligent Technology Co. Ltd. has identified GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers from Sun Yat-Sen University and affiliated organizations presented data from a study that aimed to investigate mechanisms by which the CXC chemokine receptor 3 (CXCR3) antagonist, AMG-487, acts on autoimmune uveitis. Read More
Janssen Pharmaceutica NV has divulged mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer. Read More
Researchers at Viva Star Biosciences (Suzhou) Co. Ltd. and Viva Star Biosciences (US) Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease. Read More
Researchers from Heinrich-Heine-Universität Düsseldorf (HHUD) and affiliated organizations presented the discovery of novel antimalarial agents. Read More
